Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 28 results

Firm News | 2 min read | 04.07.25

The Daily Journal Names Kent B. Goss and Jon Gurka Among Top IP Lawyers

Irvine – April 7, 2025: The Daily Journal has named Crowell & Moring’s Kent B. Goss and Jon Gurka as Top Intellectual Property Lawyers in California in 2025. The annual list recognizes California lawyers who have made significant contributions to intellectual property law over the past year.

Firm News | 9 min read | 01.02.25

Crowell & Moring Elects 12 New Partners, Promotes Four to Senior Counsel and 25 to Counsel

Crowell & Moring elected 12 new partners effective January 1, 2025. The firm also promoted four lawyers to the senior counsel and 25 associates to counsel.

Firm News | 2 min read | 12.12.24

Crowell’s Marc Richards and Adam Sussman Author “Patenting Inventions” Chapter for IICLE Intellectual Property Law Handbook

Chicago – December 12, 2024: Crowell partner Marc V. Richards and counsel Adam D. Sussman recently authored the lead chapter in the 2025 edition of the Illinois Institute of Continuing Legal Education’s Intellectual Property Law Handbook. The chapter, titled “Patenting Inventions,” covers the basics of what a patent is and what it can protect, and provides a detailed roadmap for evaluating inventions and the process to obtain a U.S. patent.
...

Client Alerts 65 results

Client Alert | 4 min read | 04.10.25

Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”

In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
...

Client Alert | 4 min read | 04.01.25

Hatch-Waxman PTE for Reissue Patents Should Be Calculated From the Original Patent’s Issue Date

On March 13, 2025, the United States Court of Appeals for the Federal Circuit issued a decision about Patent Term Extensions (PTEs) under the Hatch-Waxman Act for reissue patents. In Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254), the Court confirmed that the PTE provision under 35 U.S.C. § 156 refers to the original patent’s issue date, not the reissue patent’s issue date. Thus, the issue date of the original patent should be used when calculating the extension period.
...

Client Alert | 4 min read | 03.24.25

USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?

On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
...

Press Coverage 12 results

Publications 20 results

Publication | 12.26.24

Efficiency v Flexibility – The Patent Prosecution Highway (PPH) Program’s Pros and Cons

The Patent Prosecution Highway (PPH) program is a collaborative initiative between the United States Patent and Trademark Office (USPTO) and several foreign patent offices, created to speed up the examination process. Through the PPH, a patent application initially filed with a participating patent office (Office of Earlier Examination, or OEE) can be expedited in another participating intellectual property office, provided it meets specific requirements. According to the USPTO, PPH leverages fast-track examination procedures already in place among participating patent offices to allow applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing.  
...

Publication | 01.10.24

Patents: A Proposed Legislative Fix for Patent Eligibility Ambiguity Could Impact Litigation Strategy

Litigation Forecast 2024
A proposed overhaul of U.S. patent eligibility law could shape the patent litigation landscape in 2024, with some parties rushing to court before Congress enacts reform and others holding back on filing suit in the hope that the changes will strengthen their legal case, says Crowell & Moring partner Gang Chen.
...

Events 4 results

Event | 03.12.25 - 03.13.25, 8:00 AM CDT - 6:00 PM CDT

World Intellectual Property Review Summit

Crowell was a silver sponsor of The World Intellectual Property Review (WIPR) Summit in Chicago March 12 and 13. The conference topic was “Create A Winning IP Strategy: Overcome Market Uncertainty, Harness AI, And Improve Efficiency."

Event | 03.22.24, 5:30 PM EDT - 12:00 AM EDT

NYIPLA The 102nd Annual Dinner in Honor of the Federal Judiciary

This event, also known as the “Patent Prom”, celebrates and honors everyone who provides service in the federal judiciary, from the District Courts to Appellate Courts, including Judges, Magistrate Judges, Court Clerks, Law Clerks and their staff. Crowell hosts a cocktail reception as well as a Casino Night. There are approximately 1000 attendees at the black-tie event with many attendees stopping by Crowell’s very popular casino themed reception.

Event | 03.09.23, 1:00 PM EST - 2:00 PM EST

Minimizing Risks When Launching Smart Medical Devices

More companies than ever before are launching smart medical devices and industry growth seems endless as new products and technologies are announced daily. However, before companies push products to market, it’s crucial to understand key aspects of device approval, and company and patient protection. In this webinar, our speakers will outline intellectual property strategies, U.S. Food and Drug Administration considerations, and data cybersecurity concerns that are inherent to all smart medical devices. They will explore the legal issues that can significantly decrease the risk profile and potential liabilities throughout a product's lifecycle and create safer, more reliable products for consumers.
...

Webinars 1 result

Webinar | 07.25.24, 12:00 PM EDT - 1:00 PM EDT

The Evolving AI Legal and Policy Landscape: Mid-2024 Update

Since the November 2022 release of ChatGPT, generative AI has been a regulatory accelerator for governance of AI writ large. Individuals, organizations, industries, and governments across the world have grappled with the implications of AI, including how it is and could be regulated using existing and new legal frameworks. For example, since our December 2023 update:
...

Speaking Engagements 8 results

Podcasts 1 result

Podcast | 09.19.24

&Motion: Design Patents and the Transportation Industry

&Motion sits with Crowell's Jacob Bachman to discuss design patents and their relevance to the transportation industry.
...